Latest Eplerenone Stories
A drug known to reduce mortality rate in patients with heart failure has now been found significantly effective when administered early in patients following an acute (ST elevated) myocardial infarction.
Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively.
The aldosterone antagonist eplerenone (Inspra, Pfizer) significantly reduced the development of new onset atrial fibrillation and flutter (AFF) in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology (ESC).
CHICAGO, Nov. 14, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
NEW YORK, May 27 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC).
A study published in JAMA on October 21 by Nancy M. Albert and colleagues, exploring aldosterone antagonist usage among US patients hospitalized with heart failure, found that only one-third of patients meeting current US Clinical Practice Guidelines criteria were actually being treated.
- A trick or prank.